

	#1	#2	#3	#4	#5	#6	#7	#8	#9	#10	#11	#12
Baseline												
Behavioral addiction	PG	PG	CS	PG	PG	PG	PG	HD	PG	PG	HD	PG
Age (years)	66.88	69.40	54.62	62.03	58.33	59.85	67.45	52.18	61.74	54.45	56.13	63.90
Male sex	M	M	F	M	M	F	F	M	M	F	M	M
Duration of PD (years)	10	11	9	14	10	7	6	7	13	7	11	19
Hoehn and Yahr stage	2.5	2	1	1.5	2	2	2	2	1.5	3	1.5	3
Schwab and England stage (%)	0.9	0.9	0.8	1	1	0.9	0.9	1	0.9	0.9	0.9	1
UPDRS3 score	11	10	22	8	11	14	5	3	26	0	7	24
Cumulative LEDD (mg/day)	1129	950	950	875	1135	1439.5	800	726.08	701.57	702.8	1202.1	1460
Agonist dopaminergic adjunction	Yes	Yes	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes
Antipsychotic treatment	No	No	No	No	No	Yes	No	No	No	No	No	No
Anxiolytic treatment	No	No	No	No	No	Yes	No	No	No	No	No	No
Antidepressant treatment	No	No	No	No	No	Yes	No	No	No	No	No	No
Benzodiazepine treatment	No	No	No	No	Yes	No	No	No	No	No	No	No
MADRS score	16	7	27	8	8	5	23	6	1	10	6	4
MAS score	2	13	7	0	3	0	1	3	0	4	2	2
HAD Anxiety score	10	10	15	4	6	5	15	9	4	15	4	2
HAD Depression score	10	1	8	3	8	6	4	5	3	4	2	0
EPN-31 Positive score	17	69	25	38	44	54	47	52	44	46	60	53
EPN-31 Negative score	52	20	69	46	22	31	96	49	22	45	40	33
CGI-S	5	5	5	5	4	5	5	3	3	4	5	5
ECCA	22	26	15	16	9	32	21	17	9	5	12	31

	#1	#2	#3	#4	#5	#6	#7	#8	#9	#10	#11	#12
M6												
UPDRS3 score	23	14	12	5	6	12	13	2	31	0	15	8
Cumulative LEDD (mg/day)	1254	2150	362.68	200	751	500	300	500	5.19	201.05	600.78	1000
Agonist dopaminergic adjunction	Yes	Yes	Yes	Yes	Yes	No	No	No	No	Yes	Yes	No
Antipsychotic treatment	No	No	No	No	No	Yes	No	No	No	No	No	No
Anxiolytic treatment	Yes	No	No	No	No	Yes	No	No	No	No	No	No
Antidepressant treatment	No	No	No	No	No	No	No	Yes	No	Yes	No	No
Benzodiazepine treatment	No	No	No	No	No	No	No	No	No	Yes	No	No
MADRS score	8	5	27	12	0	2	11	0	3	5	1	6
MAS score	0	2	3	3	0	0	0	4	0	4	8	0
HAD Anxiety score	5	3	13	2	5	5	8	8	2	11	0	4
HAD Depression score	6	3	9	4	7	1	4	3	5	5	5	2
EPN-31 Positive score	17	64	23	45	56	41	39	50	33	51	61	44
EPN-31 Negative score	21	19	99	52	18	28	78	38	19	47	23	31
Right hemisphere stimulation												
Contact number	0	3	1 & 2	1	2	2	2	3	2	3	3	2
Amplitude (V)	3.0	2.0	3.0	3.2	2.5	3.0	3.0	1.6	1.8	1.7	4.5	3.0
Pulse width (μ s)	60	60	60	60	60	60	60	60	60	60	60	60
Frequency (Hz)	60	130	130	130	185	130	185	130	130	210	100	160
Left hemisphere stimulation												
Contact number	8	3	10	5	2	6	6	9	2	7	11	5
Amplitude (V)	3.0	1.5	3.0	3.2	2.5	2.6	1.2	2.0	1.5	2.8	3.5	4.5
Pulse width (μ s)	60	60	60	60	60	60	60	60	60	60	60	60
Frequency (Hz)	60	130	130	130	130	130	185	130	130	210	100	185

	#1	#2	#3	#4	#5	#6	#7	#8	#9	#10	#11	#12
M12												
UPDRS3 score	11	14	26	5	0	7	5	2	8	6	15	16
Cumulative LEDD (mg/day)	1629	2150	463.55	200	751.05	675	300	500	525	351.05	600.78	1000
Agonist dopaminergic adjunction	Yes	Yes	Yes	Yes	Yes	No	No	No	No	Yes	Yes	No
Antipsychotic treatment	No	No	No	No	No	No	No	No	No	No	No	No
Anxiolytic treatment	Yes	No	No	No	No	No	No	No	No	No	No	No
Antidepressant treatment	No	No	No	No	No	Yes	No	Yes	No	No	No	No
Benzodiazepine treatment	No	No	Yes	No	No	No	No	No	No	Yes	No	No
MADRS score	8	13	5	5	1	0	9	0	9	19	1	6
MAS score	0	4	3	0	0	1	0	4	0	1	1	0
HAD Anxiety score	7	4	9	2	4	2	8	8	1	13	0	3
HAD Depression score	5	7	5	4	8	1	5	3	9	7	5	4
EPN-31 Positive score	52	57	43	50	52	48	50	50	32	37	61	56
EPN-31 Negative score	56	18	37	61	27	28	70	38	24	48	23	26
Right hemisphere stimulation												
Contact number	0	3	1 & 2	1	2	2	2	3	1	3	3	2
Amplitude (V)	2.0	2.0	3.0	3.2	2.6	2.8	3.2	1.6	2.1	2.9	4.5	3.0
Pulse width (µs)	60	60	60	60	60	60	60	60	60	60	60	60
Frequency (Hz)	130	130	130	130	185	130	185	130	130	130	100	185
Left hemisphere stimulation												
Contact number	8	3	10	5	2	6	6	9	2	7	11	5
Amplitude (V)	2.0	1.7	3.0	3.2	2.6	2.6	1.5	2.0	2.0	1.7	3.5	4.5
Pulse width (µs)	60	60	60	60	60	60	60	60	60	60	60	90
Frequency (Hz)	130	130	130	130	130	130	185	130	130	130	100	185

CGI-S, Clinical Global Impression - Severity; CS, Compulsive Shopping; ECCA, craving behaviors scale; EPN-31, Positive and Negative Emotionality Scale; F, female; HAD, Hospital Anxiety and Depression scale; HD, Hypersexuality Disorder; LEDD, cumulative daily L-dopa equivalent daily dose; M, male; M6, month 6; M12, month 12; MADRS, Montgomery-Asberg Depression Scale; MAS, Bech-Rafaelsen Mania Scale; PD, Parkinson's Disease; PG, Pathological Gambling; UPDRS3, Unified Parkinson's Disease Rating Scale part 3.

